DEER PARK, Ill., Feb. 06, 2025 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or...
Author - David Miller
Odronextamab BLA Accepted for FDA Review for the Treatment of...
TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ:...
FDA Files Corcept’s New Drug Application for Relacorilant as...
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Mar. 3, 2025– Corcept Therapeutics...
Depemokimab Applications Accepted for Review by the US FDA for...
London, UK — 03 March 2025 — GSK plc (LSE/NYSE: GSK) today announced the US Food and...
Tolebrutinib Regulatory Submission Accepted for Priority Review...
Paris, March 25, 2025. The US Food and Drug Administration (FDA) is evaluating under priority...
Capricor Therapeutics Announces FDA Acceptance and Priority...
SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a...
FDA Issues Complete Response Letter for Etripamil for PSVT
MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals...
FDA Grants Priority Review for Biologics License Application...
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 25, 2025– Scholar Rock (NASDAQ: SRRK), a...
Otsuka Files Biologics License Application (BLA) for...
PRINCETON, N.J. and TOKYO, JAPAN March 31, 2025 – Otsuka Pharmaceutical Development &...
Aldeyra Therapeutics Receives Complete Response Letter from the...
LEXINGTON, Mass.–(BUSINESS WIRE)–Apr. 3, 2025– Aldeyra Therapeutics, Inc...